Certains contenus de cette application ne sont pas disponibles pour le moment.
Si cette situation persiste, veuillez nous contacter àObservations et contact
1. (WO2014026142) PROCÉDÉS ET COMPOSITIONS POUR ADHÉSIFS TISSULAIRES
Note: Texte fondé sur des processus automatiques de reconnaissance optique de caractères. Seule la version PDF a une valeur juridique

CLAIMS

What is claimed is:

1. A method of connecting disrupted tissue, comprising,

a. applying an effective amount of a photothermally responsive bioadhesive composition comprising an elastin-like polypeptide (ELP) and a light absorbing chromophore to disrupted tissue in need of being connected; and

b. applying an effective amount of a directed light beam to the photothermally responsive bioadhesive composition and/or the tissue.

2. A method of laser tissue welding, compris

a. applying an effective amount of a photothermally responsive bioadhesive composition comprising an ELP and a light absorbing chromophore to disrupted tissue in need of being welded; and

b. applying an effective amount of a directed light beam to the photothermally responsive bioadhesive composition and/or the tissue.

3. A method of tissue repair, comprising,

Suturing a tissue with fibers comprising a photothermally responsive composition comprising an ELP and a light absorbing chromophore;

Optionally, applying an effective amount of a photothermally responsive bioadhesive composition comprising an ELP and a light absorbing chromophore to the sutured site; and

applying an effective amount of a directed light beam to the sutures and/or to the tissue, and optionally to the photothermally responsive bioadhesive composition.

4. A method of treating colorectal disease, comprising,

applying an effective amount of a photothermally responsive bioadhesive composition comprising an ELP and a light absorbing chromophore to disrupted colorectal tissue; and

applying an effective amount of a directed light beam to the photothermally responsive bioadhesive composition and/or the tissue.

5. The method of any of Claims 1 to 4, wherein the light absorbing chromophore comprises silver nanoparticles, gold nanorods, or gold nanoparticles, or mixtures thereof.

6. The method of any of Claims 1 to 4„ wherein the light absorbing chromophore is gold nanorods.

7. The method of any of Claims 1 to 4, wherein the light absorbing chromophore crosslink the ELP.

8. The method of any of Claims 1 to 4, wherein the ELP comprises cysteine residues.

9. The method of any of Claims 1 to 4, wherein the ELP comprises at least twelve cysteine residues.

10. The method of any of Claims 1 to 4, wherein the directed light beam is a laser.

11. The method of any of Claims 1 to 4, wherein the light is near infrared.

12. The method of any of Claims 1 to 4, wherein the directed light beam generates a bulk temperature of at least a portion of the photothermally responsive bioadhesive composition above 60 °C.

13. The method of any of Claims 1 to 4, wherein the directed light beam generates a bulk temperature of at least a portion of the photothermally responsive bioadhesive composition above 80 °C.

14. The method of any of Claims 1 to 4, wherein the disrupted tissue is colorectal tissue.

15. The method of any of Claims 1 to 4, wherein the disrupted tissue is a blood or lymphatic vessel in the body.

16. The method of any of Claims 1 to 4, wherein the disrupted tissue is bowel.

17 The method of any of Claims 1 to 4, wherein the disrupted tissue is urinary tract tissue.

18. The method of any of Claims 1 to 4, wherein the disrupted tissue is skin.

19. The method of any of Claims 1 to 4, wherein the biocompatible nanocomposite further comprises an active agent.

20. The method of Claim 19, wherein the active agent comprises an antibacterial agent.

21. The method of Claim 19, wherein the active agent is a MMP inhibitor.

22. The method of Claim 19, wherein the active agent is a soluble factor, cytokine or growth factor.

23. The method of Claim 22, wherein a soluble factor comprises FGF (fibroblast growth factor), TGF-beta, EGF or other factors known as growth factors or cytokines, or known to be involved in wound healing and repair.

24. The method of Claim 21, wherein a MMP inhibitor is doxycycline.

25. The method of any of Claims 1 to 4, further comprising an encapsulated active agent.

26. The method of any of Claims 1 to 4, further comprising an active agent that is not encapsulated.

27. The method of any of Claims 1 to 4, wherein the photothermally responsive bioadhesive composition further comprises cells.

28. The method of Claim 27, wherein the cells comprise NCM460, fibroblasts or mixtures thereof.

29. The method of Claim 27, wherein the cells are encapsulated within the photothermally responsive bioadhesive composition.

30. A method of connecting disrupted tissue, comprising,

a. applying an effective amount of an energy responsive bioadhesive composition comprising an elastin-like polypeptide (ELP) and a energy absorbing material to disrupted tissue in need of being connected; and b. applying an effective amount of a directed energy source to the photothermally responsive bioadhesive composition and/or the tissue.

31. The method of Claim 30, wherein the energy absorbing material comprises magnetothermal particles.

32. The method of Claim 31, wherein the magnetothermal particles comprise iron oxide.

33. The method of Claim 30, wherein the directed energy source is a directed magnetic frequency device.

34. The method of Claim 30, wherein the directed energy source is a directed radio frequency device.